BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA Oral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
